Bryan Gilburg - China

“The Thai FDA has optimized Market Authorization by eliminating some procedural steps and reducing service times.”

Noi Suwannabot

General Manager, Asia Actual Thailand

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Important Documents and Links

Sign Up For Our Newsletter to Stay Informed

Sign Up

Thai FDA Reduces Application Review Time

Taking Action to Realize the Prime Minister’s Policy

On February 21st, 2024, the Thai FDA gave a press release responding to the Prime Minister’s policy to increase service potential by providing data to demonstrate that their digital work system has optimized market access by reducing application processing time. Additionally, the Secretary General emphasized the TFDA’s continued commitment to consumer safety and gave assurances that a synthesis of health product security and entrepreneurial development are a top priority. This is welcome news as the TFDA recently implemented new regulations in 2021 and are keeping a close eye on their performance and implementation.

The press release for this development can be found here. For an English translation, please click here.

TFDA Halves Application Review Times

After reviewing 245 health product approval processes, the TFDA has reduced the steps and service times for operators. For cases of permission requests to produce or import medical devices, the TFDA has reduced the total number of service days by 50 percent or more. Based on data gathered by the TFDA, there has also been a much more expedited review of product registrations without Expert Review, with a reduction of 215 to 86 working days.

It was Dr. Narong Aphikulwanich, the Secretary of the Food and Drug Administration in Thailand, who announced that the policy was being changed after an order by Chonnan Srikaew, the Minister of Public Health, who was acting on the Prime Minister’s new policy declaration.

The FDA One Platform and Other Updates

The TFDA holds its service system in high regard, which is why it has been continuously updated. The FDA One Platform consists of e-Service, e-Submission, e-Payment, e-Review, e-Tracking, and e-License. What’s more, an e-Consult system which boasts online consulting services. Use of the FDA One Platform enables service recipients to access service any time and any place from all around the world thus reducing cost and travel time. The One Platform aligns with the FDA’s concept of “Smart FDA: Anywhere, Anytime, Anyone”. Before the One Platform, service users had to allot time for each application procedure as their physical presence was required. With the One Platform, in-person application review is no longer required. On top of that, the TFDA has also reduced its internal review times. Overall, service users should be pleased with this comprehensive time reduction and accessible service system. 

One Stop Service Center (OSSC)

The OSSC building is a new heath product service center meant to house Smart FDA operations (i.e. the One Platform, and Care D+ Heart). It is the epicenter of innovation, technology and digital working systems for the Thai FDA. By centralizing these operations, the FDA aspires to continue providing service users with convenient, concise, and timely service(s).

FDA Care D+

In addition to these procedural changes, the TFDA has established the FDA Care D+  Coordination Team to personify the new online platform. For service users in need of human guidance, the Care D+ Coordination Team is there to help. Pointedly, they have employed the slogan: “your heart, our heart”, to demonstrate empathy, promote understanding and reduce any communication gaps. 

To read more about the One Platform, OSSC, and Care D+ Heart, please see the Executive Activity Announcement from the TFDA posted December 8th, 2023.

With regard to questions or comments,  feel free to contact Asia Actual today.

Come Grow with Us

Please contact Asia Actual with any questions or requests for support in Thailand. We have offices staffed by experienced, bilingual regulatory and commercial professionals in the major capital cities of Asia. Our mission is to provide a stable, reliable local platform so that our clients can grow their sales in challenging Asian markets.


Blog Posts

Australia SaMD Transition Deadline

Australia’s SaMD Regulatory Deadline

Beginning on November 1st, 2024, Australia's Therapeutic Goods Administration will implement new rules surrounding software as a medical device (SaMD). While some SaMD will require additional regulatory requirements, other SaMD will be exempted from some, or excluded completely, from the new regulations.
Thai FDA Documentation Exemptions for Concise and Full Regulatory Pathways

Thai FDA Regulatory Documentation Exemptions

March 12, 2024: the Thai FDA released draft guidance updating the list of required documentation for Full and Concise Evaluation. For manufacturers registering a medical device in Thailand, certain documents are no longer required.
Hong Kong MDD adds Singapore HSA to Reference Country List

Hong Kong MDD Adds Singapore as Reference Country

Starting April 2nd, 2024, the Hong Kong Medical Device Division (MDD) accepts, on a regular basis, the marketing approvals obtained from the the Health Sciences Authority (HSA) of Singapore as a support of compliance of medical device to the "Essential Principles of Safety and Performance of Medical Devices" (Technical Reference: TR-004) under MDACS.